Gabriella Nilsson Hall is a Senior Scientist in the Cell Therapy Bioprocessing Team, within the Cell Therapy Department of BioPharmaceuticals R&D at AstraZeneca. Gabriella is responsible for developing and delivering efficient experimental design approaches in support of cell therapy projects while working within an international, highly cross-disciplinary environment with innovative techniques and technologies within areas such as the scalable closed GMP-ready production of pluripotent, immune and tissue-engineered products
Gabriella joined AstraZeneca from Katholieke Universiteit Leuven (KU Leuven) in Belgium where she received her PhD in Biomedical Sciences in 2020. During her doctoral studies, Gabriella cultured human adult stem cells for differentiation towards the mesenchymal lineage and chondrocytes derived from induced pluripotent stem cells (iPSC). Focus was on developing a proof-of-concept of using cartilaginous microtissues as building blocks to generate larger tissues for healing long bone and osteochondral defects. Her work entailed in vitro and in vivo analysis of single microtissues and assemblies. She then continued as a post-doctoral researcher at KU Leuven to pursue process adaptations for future scale-up of microtissue culture and assembly into larger tissues.